Today: 13 June 2026
AMD Earnings Tonight Could Decide Whether Its AI Stock Rally Has Gone Too Far
5 May 2026
2 mins read

AMD Earnings Tonight Could Decide Whether Its AI Stock Rally Has Gone Too Far

NEW YORK, May 5, 2026, 16:02 EDT

Advanced Micro Devices climbed 4.2% to $355.92 late Tuesday ahead of quarterly earnings, a key moment for investors wondering if the AI-chip surge has run out of steam. Just a day earlier, an HSBC downgrade had briefly dragged the stock down. Nvidia edged lower. Intel, meanwhile, posted strong gains during the session.

Timing’s key here. AMD will release its fiscal first-quarter earnings after the U.S. bell, and management will address investors at 5 p.m. ET. That puts the spotlight directly on demand for its server processors and AI chips as soon as results drop.

Wall Street wants to see growth: Analysts at FactSet, according to MarketWatch, are calling for revenue to hit about $9.9 billion, with adjusted earnings at $1.29 a share—both figures up by about a third from the same period last year. The real spotlight, though, is on data-center revenue, a segment closely linked to AI. That’s forecast to jump 53% to $5.6 billion.

The question isn’t about AMD’s growth—it’s about the pace, especially after the stock’s sharp run-up. HSBC’s Frank Lee downgraded AMD from “buy” to “hold,” pointing out he doesn’t see room for a positive earnings surprise. The analyst cited tougher expectations for server CPUs, which are the core chips powering servers as well as personal computers. Stocktwits

CNBC’s Jim Cramer pushed back on that call, telling Technobezz that AMD’s CPU business is gaining ground as agentic AI — think software handling tasks without much human input — picks up inside data centers. “CPUs are what is being used by agents,” Cramer said, and he sees room for AMD shares to climb sharply higher. Technobezz

Not everyone is on the same page. C.J. Muse at Cantor Fitzgerald is calling for a “strong beat” from AMD, with first-quarter revenue pegged at $10.4 billion—topping the $9.9 billion FactSet consensus. He points to robust server and PC demand, plus firmer CPU prices, as the drivers. MarketWatch

Competition is fierce. Nvidia still owns the GPU market—those chips are key for AI training and inference. Intel’s latest gains have some investors betting that AMD could be catching a tailwind from higher CPU demand. Unlike Intel, which controls more of its own fabs, AMD’s manufacturing is mostly in the hands of Taiwan Semiconductor Manufacturing Co.

AMD’s February guidance did little to settle investor nerves. The chipmaker projected first-quarter revenue in the neighborhood of $9.8 billion, swinging by $300 million either way. But Reuters noted that this estimate factored in some AI-chip sales to China, and analysts flagged ongoing concerns about heavy reliance on a few customers and the competitive pressure from Nvidia.

The bull thesis now stretches past just the upcoming quarter. Motley Fool’s John Ballard noted AMD shares soared roughly 75% over the past month, yet he maintained the valuation wasn’t out of line given management’s longer-range profit goals. Ballard pointed to Meta’s intentions to use AMD’s Instinct GPUs, along with a previous agreement with OpenAI.

Strong results might not cut it here. Yahoo Finance pointed out that AMD shares could drop after earnings, while Investopedia noted options markets were pricing in a swing of up to 8% either way by week’s end.

That doesn’t give AMD much leeway to disappoint. A clear beat, firmer data-center signals, and any indication that TSMC supply won’t hold back shipments could keep the rally rolling. But if the report just matches expectations, the stock’s latest surge could quickly become its biggest headache.

Stock Market Today

  • Ascletis Pharma Stock Falls 41.6% in a Month, Valuation Mixed Amid Losses
    June 13, 2026, 12:37 AM EDT. Ascletis Pharma (SEHK:1672) shares dropped 4.4% last week and 41.6% over the past month, raising questions about its valuation. The stock trades at a price-to-book (P/B) ratio of 4.7x, above the Hong Kong Biotech sector average of 3.2x but below a peer group average of 12.5x, signaling mixed valuation metrics. The company remains unprofitable with a negative return on equity of 18.61%, making earnings-based measures less relevant. While longer-term returns remain positive, recent revenue and net income weaknesses alongside ongoing losses pose risks. Investors are advised to review underlying data carefully before deciding on Ascletis Pharma's stock prospects amid a cautious market sentiment.

Latest articles

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

13 June 2026
SGH closed at A$41.51, up 0.70% but underperformed the S&P/ASX 200’s 1.98% surge, as investors weighed solid cash flow and Boral margin gains against a high 36.03 P/E, mixed demand, and M&A risk; the next key catalyst is FY26 results on August 11, with analysts’ average target at A$47.64, 14.76% above Friday’s close.
NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

13 June 2026
NCR Voyix soared 10.25% to $7.85, far outpacing the market, as investors focus on the company’s 2026 cash-flow and earnings targets; the next key catalyst is the Q2 2026 earnings update, with stock valuation appearing low if management delivers on margin and cash-flow goals, but risks remain with declining reported revenue and high debt.
Pool Corporation Stock Sinks as CEO Exit and Investor Day Delay Raise Fresh Doubts
Previous Story

Pool Corporation Stock Sinks as CEO Exit and Investor Day Delay Raise Fresh Doubts

Super Micro Stock Jumps As AI Server Maker’s Profit Outlook Clears A Margin Test
Next Story

Super Micro Stock Jumps As AI Server Maker’s Profit Outlook Clears A Margin Test

Go toTop